OncoTherapy Science (TSE:4564) Total Liabilities: 円217.4 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4564 OncoTherapy Science Inc TSE:4564
50 GF Score
Price 円20.00
GF Value 円16.92
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is OncoTherapy Science Total Liabilities?

OncoTherapy Science TSE:4564 -4.76% 50 Total Liabilities is 円217.4 Mil as of Mar. 2026. GuruFocus rates TSE:4564 with a GF Score™ of 50/100 and a GF Value™ of 円16.92 (Modestly Overvalued). The stock has 1 warning sign investors should review.

OncoTherapy Science's Total Liabilities for the quarter that ended in Mar. 2026 was 円217.4 Mil.

OncoTherapy Science's quarterly Total Liabilities declined from Mar. 2025 (円426.09 Mil) to Sep. 2025 (円289.18 Mil) and declined from Sep. 2025 (円289.18 Mil) to Mar. 2026 (円217.37 Mil).

OncoTherapy Science's annual Total Liabilities declined from Mar. 2024 (円513.61 Mil) to Mar. 2025 (円426.09 Mil) and declined from Mar. 2025 (円426.09 Mil) to Mar. 2026 (円217.37 Mil).

OncoTherapy Science Total Liabilities Historical Data

* Premium members only.

The historical data trend for OncoTherapy Science's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoTherapy Science Total Liabilities Chart

OncoTherapy Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 704.97 656.27 513.61 426.09 217.37

OncoTherapy Science Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 513.61 547.74 426.09 289.18 217.37
TSE:4564
50GF Score
OncoTherapy Science Inc TSE:4564
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OncoTherapy Science Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

OncoTherapy Science's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=169.967+(0+47.406
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=217.4

Total Liabilities=Total Assets (A: Mar. 2026 )-Total Equity (A: Mar. 2026 )
=2359.354-2141.981
=217.4

OncoTherapy Science's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=169.967+(0+47.406
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=217.4

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=2359.354-2141.981
=217.4

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of 円217.4 Mil mean?
OncoTherapy Science (TSE:4564) has a Total Liabilities of 円217.4 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for OncoTherapy Science and its competitors.
Is OncoTherapy Science's Total Liabilities too high?
OncoTherapy Science's current Total Liabilities is 円217.4 Mil. Overall, OncoTherapy Science has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's Total Liabilities compare to VRTX and REGN?
OncoTherapy Science's Total Liabilities of 円217.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for OncoTherapy Science and its competitors. OncoTherapy Science's current Total Liabilities is 円217.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
Based on GuruFocus' analysis, OncoTherapy Science (TSE:4564) is currently considered Modestly Overvalued. The stock's GF Value™ is 円16.92, compared to a current price of 円20.00 — trading 18.2% above its estimated fair value. The current Total Liabilities is 円217.4 Mil. OncoTherapy Science's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For OncoTherapy Science (TSE:4564), the current Total Liabilities is 円217.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OncoTherapy Science (TSE:4564) Overvalued in 2026?

Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued. The current stock price of 円20.00 is trading 18.2% above its estimated GF Value™ of 円16.92. GuruFocus considers OncoTherapy Science to be Modestly Overvalued.

Key valuation signals for TSE:4564:

  • Total Liabilities: 円217.4 Mil
  • GF Value™: 円16.92 vs. price of 円20.00 (18.2% above fair value)
  • GF Score™: 50/100 with 1 warning sign

No single metric tells the full story. See the TSE:4564 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OncoTherapy Science Business Description

Other Exchanges 30O:Germany
Address 11th Floor, Kanagawa Science Park R&D, 3-2-1 Sakado, Kanagawa, Kawasaki, JPN, 213-0012
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
50GF Score

Get the complete analysis for TSE:4564

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円20.00
Price
円16.92
GF Value